RankAlpha logo
Back to Rankings

TECX

Tectonic TherapeuticC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
TX2100 cleared an initial safety and pharmacokinetic hurdle, and planned HHT patient studies could add a second clinical value driver. A positive TX45 Phase 2 efficacy readout would be the larger upside event.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.5.
What can break
Clinical timelines may slip; future development spending or ATM issuance could dilute shareholders despite the stated runway. [#SEC-8K-2026-08-06]
Momentum
8
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $38.00 · Bear $11.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $71.00
Why
Momentum8 · Δ7d +1.5
Value41 · Δ7d -0.1
Sentiment74 · Δ7d +4.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +4.5.

Contradictions & invalidation

  • • Clinical timelines may slip; future development spending or ATM issuance could dilute shareholders despite the stated runway. [#SEC-8K-2026-08-06]
  • • Healthy-volunteer TX2100 safety and pharmacokinetic results do not demonstrate efficacy or repeat-dose safety in HHT patients; anti-drug antibody results were pending. [#PR-2026-09-29]
  • • TX2100 has not shown HHT patient efficacy; anti-drug antibody results were pending at the September release.

Catalyst clock

2026-10-16

Detailed TX2100 Phase 1a data

Lead driver: Sentiment · See AI snapshot
Momentum
8
8% active weight
Current posture
7d trendFlat
Δ7d
+1.5
Δ21d
+1.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
74
45% active weight
Current posture
7d trendFlat
Δ7d
+4.5
Δ21d
+3.9
Why this grade

Composite grade C. Momentum 8.1 / Value 40.6 / Sentiment 74.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method

B+
Bull case
0%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Most likely
B
Base case
0%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$392.36M
Beta
1.59
Shares Out
19.55M
P/E (TTM) · Derived
-5.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.21
Rev YoY
-
EPS YoY
+9.8%
Gross Margin
-
Op Margin
-
Net Debt
-$253.11M
Current Ratio
22.29
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data